AI Engines For more Details: Perplexity Kagi Labs You
Pain Relief: Flufenamic acid is effective in relieving mild to moderate pain associated with conditions such as headache, toothache, menstrual cramps (dysmenorrhea), musculoskeletal pain, and postoperative pain. It works by inhibiting the production of prostaglandins, which are chemicals in the body that promote pain and inflammation.
Inflammatory Conditions: Flufenamic acid can help reduce inflammation in conditions such as arthritis (including rheumatoid arthritis and osteoarthritis), tendonitis, bursitis, and gout. By inhibiting prostaglandin synthesis, it helps alleviate pain, swelling, stiffness, and joint tenderness associated with these inflammatory disorders.
Fever Reduction: Flufenamic acid has antipyretic properties, meaning it can lower fever by acting on the hypothalamus in the brain, which regulates body temperature. It is commonly used to reduce fever associated with infections or inflammatory conditions.
Menstrual Disorders: Flufenamic acid may be used to manage symptoms of menstrual disorders, including dysmenorrhea (painful menstrual periods) and menorrhagia (heavy menstrual bleeding). It helps relieve menstrual cramps and reduce excessive menstrual bleeding by inhibiting uterine contractions and reducing prostaglandin levels.
Migraine Headaches: Flufenamic acid has been studied for its potential effectiveness in the treatment of migraine headaches. It may help alleviate migraine pain and associated symptoms, such as nausea and sensitivity to light and sound, although it is not commonly used for this purpose compared to other migraine medications.
Dosage and Administration: Flufenamic acid is typically taken orally in the form of tablets or capsules. The dosage and frequency of administration depend on the specific condition being treated, the severity of symptoms, and individual patient factors. It is important to follow the dosage instructions provided by a healthcare professional to ensure safe and effective use of the medication.
Side Effects: Common side effects of flufenamic acid may include gastrointestinal disturbances such as nausea, vomiting, indigestion, abdominal pain, diarrhea, and gastritis. Long-term use or high doses of NSAIDs like flufenamic acid may increase the risk of gastrointestinal ulcers, bleeding, and perforation. Other potential side effects include headache, dizziness, drowsiness, and allergic reactions.
Precautions and Contraindications: Flufenamic acid should be used with caution in individuals with a history of gastrointestinal disorders, peptic ulcer disease, kidney or liver impairment, cardiovascular disease, or asthma. It is contraindicated in patients with a known hypersensitivity to NSAIDs or a history of allergic reactions to aspirin or other NSAIDs.
Drug Interactions: Flufenamic acid may interact with other medications, including anticoagulants (blood thinners), antiplatelet drugs, corticosteroids, selective serotonin reuptake inhibitors (SSRIs), and certain antihypertensive medications. It is important to inform healthcare providers about all medications being taken to avoid potential drug interactions.
Pregnancy and Lactation: Flufenamic acid should be avoided during pregnancy, especially during the third trimester, due to the potential risk of adverse effects on the fetus and complications during labor and delivery. It may also pass into breast milk and should be used with caution in nursing mothers.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.6 | 0.6 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 4.9 | 0.6 | 7.17 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.4 | 0.25 |
| Allergic Rhinitis (Hay Fever) | 2.7 | 2.6 | 0.04 |
| Allergies | 5.9 | 3.1 | 0.9 |
| Allergy to milk products | 1.9 | 1.6 | 0.19 |
| Alopecia (Hair Loss) | 1 | 1 | |
| Alzheimer's disease | 5.9 | 5.2 | 0.13 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3 | 0.8 | 2.75 |
| Ankylosing spondylitis | 4 | 1.6 | 1.5 |
| Anorexia Nervosa | 1.6 | 2.9 | -0.81 |
| Antiphospholipid syndrome (APS) | 1.2 | 1.2 | |
| Asthma | 5.2 | 2.7 | 0.93 |
| Atherosclerosis | 2.3 | 1.5 | 0.53 |
| Atrial fibrillation | 3.2 | 2.2 | 0.45 |
| Autism | 9.3 | 9.2 | 0.01 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 2.2 | 2.2 | |
| Bipolar Disorder | 2.1 | 1.7 | 0.24 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 0.9 | 0.9 | |
| Cancer (General) | 0.9 | 2.8 | -2.11 |
| Carcinoma | 4.1 | 2 | 1.05 |
| Celiac Disease | 2.5 | 3.1 | -0.24 |
| Cerebral Palsy | 1.5 | 1.3 | 0.15 |
| Chronic Fatigue Syndrome | 5.6 | 4.8 | 0.17 |
| Chronic Kidney Disease | 3.8 | 1.5 | 1.53 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 2 | 2 | 0 |
| Chronic Urticaria (Hives) | 1.6 | 1.4 | 0.14 |
| Coagulation / Micro clot triggering bacteria | 1.6 | 1.3 | 0.23 |
| Cognitive Function | 2.5 | 1.6 | 0.56 |
| Colorectal Cancer | 7.5 | 2.2 | 2.41 |
| Constipation | 1.9 | 0.7 | 1.71 |
| Coronary artery disease | 2.2 | 2.4 | -0.09 |
| COVID-19 | 10.4 | 10.3 | 0.01 |
| Crohn's Disease | 8.5 | 5 | 0.7 |
| Cushing's Syndrome (hypercortisolism) | 0.8 | -0.8 | |
| cystic fibrosis | 0.9 | 1.9 | -1.11 |
| d-lactic acidosis (one form of brain fog) | 0.3 | 0.3 | |
| deep vein thrombosis | 2.5 | 1.4 | 0.79 |
| Denture Wearers Oral Shifts | 1.7 | 1.7 | |
| Depression | 11.7 | 7.4 | 0.58 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 2.1 | 2.2 | -0.05 |
| Endometriosis | 2.6 | 2.3 | 0.13 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 3.5 | 2.1 | 0.67 |
| erectile dysfunction | 1.4 | 0.3 | 3.67 |
| Fibromyalgia | 3.1 | 2.1 | 0.48 |
| Functional constipation / chronic idiopathic constipation | 5.8 | 4.3 | 0.35 |
| gallstone disease (gsd) | 3.2 | 1.2 | 1.67 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.2 | 1.2 | 0.83 |
| Generalized anxiety disorder | 3 | 2.1 | 0.43 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2 | 0.6 | 2.33 |
| Graves' disease | 1.9 | 2.7 | -0.42 |
| Gulf War Syndrome | 0.9 | 1.9 | -1.11 |
| Halitosis | 1.8 | 0.3 | 5 |
| Hashimoto's thyroiditis | 2.9 | 1 | 1.9 |
| Heart Failure | 4.9 | 1.4 | 2.5 |
| hemorrhagic stroke | 0.7 | 0.7 | |
| Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
| High Histamine/low DAO | 1.3 | 0.6 | 1.17 |
| hypercholesterolemia (High Cholesterol) | 0.8 | 0.2 | 3 |
| hyperglycemia | 2.3 | 1.5 | 0.53 |
| Hyperlipidemia (High Blood Fats) | 0.7 | 0.3 | 1.33 |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 3.9 | 5.8 | -0.49 |
| Hypothyroidism | 0.1 | 1 | -9 |
| Hypoxia | 2.5 | 0.3 | 7.33 |
| IgA nephropathy (IgAN) | 1.9 | 5.4 | -1.84 |
| Inflammatory Bowel Disease | 8.9 | 8.2 | 0.09 |
| Insomnia | 1.5 | 2.5 | -0.67 |
| Intelligence | 1.6 | 0.6 | 1.67 |
| Intracranial aneurysms | 1.4 | 0.6 | 1.33 |
| Irritable Bowel Syndrome | 7.3 | 5.5 | 0.33 |
| ischemic stroke | 2.9 | 1.4 | 1.07 |
| Liver Cirrhosis | 6.5 | 4 | 0.63 |
| Long COVID | 7.2 | 7 | 0.03 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 1.2 | 0.7 | 0.71 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.5 | 0.9 | 0.67 |
| ME/CFS with IBS | 1 | 1.3 | -0.3 |
| ME/CFS without IBS | 1.8 | 1.2 | 0.5 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 2.1 | 0.7 | 2 |
| Metabolic Syndrome | 6.8 | 7.5 | -0.1 |
| Mood Disorders | 12.1 | 6.8 | 0.78 |
| multiple chemical sensitivity [MCS] | 0.9 | 0.1 | 8 |
| Multiple Sclerosis | 6.1 | 5.5 | 0.11 |
| Multiple system atrophy (MSA) | 0.9 | 0.7 | 0.29 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 2.8 | -8.33 |
| Neuropathy (all types) | 0.8 | 2.2 | -1.75 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.8 | 0.8 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 5.5 | 4.6 | 0.2 |
| NonCeliac Gluten Sensitivity | 1.5 | 0.6 | 1.5 |
| Obesity | 8.8 | 8.5 | 0.04 |
| obsessive-compulsive disorder | 6.1 | 2.8 | 1.18 |
| Osteoarthritis | 3.1 | 1.3 | 1.38 |
| Osteoporosis | 2.5 | 1 | 1.5 |
| pancreatic cancer | 1.2 | 0.3 | 3 |
| Parkinson's Disease | 7.5 | 6.2 | 0.21 |
| Polycystic ovary syndrome | 7.1 | 2.6 | 1.73 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 0.6 | 1.7 | -1.83 |
| Primary sclerosing cholangitis | 2.8 | 3 | -0.07 |
| Psoriasis | 2.8 | 3 | -0.07 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 6.9 | 3.5 | 0.97 |
| Rosacea | 0.6 | 0.7 | -0.17 |
| Schizophrenia | 6.9 | 3.2 | 1.16 |
| scoliosis | 0.6 | 0.9 | -0.5 |
| Sjögren syndrome | 3.2 | 2.3 | 0.39 |
| Sleep Apnea | 1.6 | 1.8 | -0.13 |
| Slow gastric motility / Gastroparesis | 1.1 | 0.3 | 2.67 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.9 | 0.6 | 2.17 |
| Stress / posttraumatic stress disorder | 2.4 | 3 | -0.25 |
| Systemic Lupus Erythematosus | 4.4 | 2.4 | 0.83 |
| Tic Disorder | 1.4 | 1.2 | 0.17 |
| Tourette syndrome | 0.4 | 0.3 | 0.33 |
| Type 1 Diabetes | 4.3 | 4.3 | 0 |
| Type 2 Diabetes | 7.9 | 7.2 | 0.1 |
| Ulcerative colitis | 5.6 | 7.3 | -0.3 |
| Unhealthy Ageing | 4.9 | 2 | 1.45 |
| Vitiligo | 2.5 | 1.2 | 1.08 |
